OOIR: Observatory of International Research

Papers

(The H4-Index of npj Precision Oncology is 39. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-10-01 to 2025-10-01.)

Article	Citations
An automated deep learning pipeline for EMVI classification and response prediction of rectal cancer using baseline MRI: a multi-centre study	263
The dynamic immune behavior of primary and metastatic ovarian carcinoma	128
Exosome- transported FER inhibitor suppresses progression of diffuse large B-cell lymphoma via regulating AJUBA/Hippo axis	118
Sub-regional radiomics combining multichannel 2-dimensional or 3-dimensional deep learning for predicting neoadjuvant chemo-immunotherapy response in esophageal squamous cell carcinoma: a multicenter	111
Improved prediction of MAPKi response duration in melanoma patients using genomic data and machine learning	108
Multi-modal characterization of metabolic and immune gene clusters in adrenocortical carcinoma treatment	105
Complement activation in tumor microenvironment after neoadjuvant therapy and its impact on pancreatic cancer outcomes	103
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP	98
Development and testing of a polygenic risk score for breast cancer aggressiveness	97
Mucin-1: a promising pan-cancer therapeutic target	81
Constitutional mismatch repair deficiency mimicking Lynch syndrome is associated with hypomorphic mismatch repair gene variants	68
A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada	66
Analyses of canine cancer mutations and treatment outcomes using real-world clinico-genomics data of 2119 dogs	61
A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3	61
Barriers and opportunities in pancreatic cancer immunotherapy	60
BRAF v600E–mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study	58
Tumor break load quantitates structural variant-associated genomic instability with biological and clinical relevance across cancers	56
Imaging and AI based chromatin biomarkers for diagnosis and therapy evaluation from liquid biopsies	55
Genome-wide analyses reveals an association between invasive urothelial carcinoma in the Shetland sheepdog and NIPAL1	54
Developing survival prediction models in colorectal cancer using epigenome-wide DNA methylation data from whole blood	53
Patient-level proteomic network prediction by explainable artificial intelligence	52
Author Correction: An automated deep learning pipeline for EMVI classification and response prediction of rectal cancer using baseline MRI: a multi-centre study	51
Circulating tumor DNA in ALK-positive anaplastic large cell lymphoma: a proof-of-concept study	50
Grading of lung adenocarcinomas with simultaneous segmentation by artificial intelligence (GLASS-AI)	50
PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells	49

Interferon signaling and ferroptosis in tumor immunology and therapy	49
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates	49
An international multi-institutional validation study of the algorithm for prostate cancer detection and Gleason grading	48
Erigoster B targeting DECR1 induces ferroptosis of breast cancer cells via promoting phosphatidylcholine/arachidonic acid metabolism	46
m6A reader IGF2BP2-stabilized lncRNA LHX1-DT inhibits renal cell carcinoma (RCC) cell proliferation and invasion by sponging miR-590-5p	45
Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays	45
Multiregional transcriptomic profiling provides improved prognostic insight in localized non-small cell lung cancer	43
User-centered design approach to visualize PROMs for molecular tumor boards	42
Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab	42
Stage-dependent spatial distribution and prognostic value of CD8+ tissue-resident memory T cells in NSCLC	42
A universal immunohistochemistry analyzer for generalizing AI-driven assessment of immunohistochemistry across immunostains and cancer types	42
Genomic and transcriptomic analyses identify distinctive features of triple-negative inflammatory breast cancer	41
Single-cell landscape of bronchoalveolar immune cells in patients with immune checkpoint inhibitor-related pneumonitis	41
Enhanced efficacy of ipilimumab plus nivolumab in angiogenic subtypes of metastatic clear-cell renal cell carcinoma	40
Targeting Nrf2/PHKG2 axis to enhance radiosensitivity in NSCLC	39
Establishing predictive machine learning models for drug responses in patient derived cell culture	39
Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma	39
Real-world experience of Molecular Tumour Boards for clinical decision-making for cancer patients	39